Profitability Ratios
| Ratio |
Value |
| GP Margin |
94.1% |
| EBIT Margin |
-27.8% |
| EBITDA Margin |
-27.6% |
| Operating Margin |
-31.3% |
| Pretax Margin |
-30.1% |
| Cont. Ops Margin |
-30.1% |
| Net Margin |
-30.1% |
| Bottom Line Margin |
-30.1% |
Liquidity Ratios
| Ratio |
Value |
| Current Ratio |
4.01 |
| Quick Ratio |
3.77 |
| Solvency Ratio |
-0.437 |
| Cash Ratio |
0.64 |
Valuation Ratios
| Ratio |
Value |
| Price/Earnings |
|
| PEG Ratio |
1.10 |
| Forward PEG |
1.10 |
| Price/Book |
21.68 |
| Price/Sales |
13.63 |
| Price/FCF |
-68.75 |
| Price/Op Cash Flow |
-68.92 |
Debt Ratios
| Ratio |
Value |
| Debt/Assets |
0.2813 |
| Debt/Equity |
0.5880 |
| Debt/Capital |
0.3703 |
| Long-Term Debt/Capital |
0.3651 |
| Financial Leverage |
2.09 |
Cash Flow Ratios
| Ratio |
Value |
| Working Capital Turnover |
1.07 |
| Operating Cash Flow Ratio |
-0.611 |
| Operating Cash Flow/Sales |
-19.8% |
| Free Cash Flow/Operating Cash Flow |
100.2% |
Coverage Ratios
| Ratio |
Value |
| Debt Service Coverage |
-11.34 |
| Interest Coverage |
-13.4518 |
| Short-Term Operating Cash Flow Coverage |
-186.20 |
| Operating Cash Flow Coverage |
-0.53 |
| Capital Expenditure Coverage |
-405.90 |
| Dividend + Capital Expenditure Coverage |
-405.90 |
Dividend Ratios
| Ratio |
Value |
| Payout Ratio |
0.0000% |
| Dividend Yield |
0.0000% |
| Dividend Yield % |
0.0000% |
| Dividend Per Share |
0.0000 |
Per Share Ratios
| Ratio |
Value |
| Revenue/Share |
42.72 |
| EPS |
-12.850 |
| Debt/Share |
16.7899 |
| Cash/Share |
43.84 |
| Book Value/Share |
26.86 |
| Tangible BV/Share |
26.54 |
| Equity/Share |
26.86 |
| Operating Cash Flow/Share |
-8.449 |
| Capital Expenditure/Share |
0.021 |
| FCF/Share |
-8.470 |
Other Ratios
| Ratio |
Value |
| Net Income/Earnings Before Tax |
1.000 |
| Earnings Before Tax/EBIT |
0.961 |
| Price/Fair Value |
21.68 |
| Debt/Market Cap |
0.0266 |
| Effective Tax Rate |
0.0% |
| Enterprise Value Multiple |
-49.99 |
MDGL - Madrigal Pharmaceuticals, Inc.